RxSight (RXST) Stock Forecast & Price Target

RxSight is viewed positively because its core light adjustable lens platform remains differentiated, and the Alcon collaboration underscores the value of its technology while creating an additional intermediate-term upside path. Despite 3Q26 revenue missing consensus amid competitive pressures, restructuring, and territory changes, the company is refocusing on utilization across its installed base, with pockets of strength where physician engagement and practice integration have improved. The outlook is also supported by expectations that cash burn will improve as LALs become a larger mix of revenue, and that growth could resume in 2H26 or 2027 if utilization recovers, even with flat to down LDD placements.

RxSight is facing a weakening core business as 3Q26 revenue fell 19% year over year to $24.6M, below consensus, with LAL sales of 23,128 units and only 3 LDDs sold, underscoring softer utilization and limited capital equipment demand. Competitive pressure and salesforce disruption are hurting execution, while gross margin slipped to 73.6% due to higher inventory costs and reserves and operating expenses rose to $36.6M, deepening earnings pressure with adjusted EPS of -$0.21. The absence of a FY outlook after guidance withdrawal, combined with leadership transitions, evolving commercial strategy, and risks of further utilization declines or dilutive financing, supports a cautious fundamental outlook.